Manzo announces positive probiotic results
Manzo Pharmaceuticals, Inc. has announced positive results from the 6 month animal study of Lacto-Freedom
Manzo Pharmaceuticals, Inc. has announced positive results from the 6-month animal study of Lacto-Freedom, the company's lactase producing probiotic. This successful testing brings Manzo Pharmaceuticals, and partner, Celprogen, Inc., one step closer to human clinical trials.
The 6-month study was conducted by Celprogen, Inc. using laboratory rats to test the new probiotic treatment. Lab rats are the ideal mammals to test because they are naturally lactose intolerant.
After 6 months the rats given the treatment showed no negative side-effects, even at very high doses. All doses from low to high concentration were very successful at colonising the intestines and producing lactase, which enabled rats to digest lactose.
In addition, the blood glucose levels of the rats was significantly higher after treatment, and for the full 6 months, demonstrating that the lactose in their diet was properly broken down into glucose and galactose. This effect lasted for a full 6 months after the administration of the probiotic was discontinued.This long-lasting residual effect is unique and is far superior to any other lactose intolerance treatment option currently on the market.
As approximately 25% of the population in the United States is lactose intolerant, Manzo Pharmaceuticals and Celprogen are both confident that there will be a huge demand for this product.
Manzo Pharmaceuticals, Inc. also welcomes Dean Franchino to the project. Mr Franchino has experience in the production of nutritional and pharmaceutical grade products, quality control, FDA regulations, research and development of new products and extensive knowledge of medical equipment. This will prepare Manzo Pharmaceuticals for the next phase of business after human trials, which will be to manufacture, package and distribute Lacto-Freedom globally.
